Pinealon
Peptide bioregulator (Glu-Asp-Arg)
Pinealon is Glu-Asp-Arg, and it is the one compound in this cohort with a published molecular model of where it is supposed to bind. That makes it the best place to look at what these mechanism papers actually say — including the word the authors themselves use when they describe cell entry.
Pinealon quick facts
| Reported research dose (Injectable) | 2mg-5mg |
| Route | Subq |
| Frequency | 1x Daily AM |
| Half-life | ~2-4 hrs |
| Forms | Injectable, Nasal |
| Evidence level | Russian studies; limited |
| Other forms available | Nasal — dosed differently |
Bioregulators are run in short courses, not continuously — that's how they're studied. Pineal-directed, which is why it is usually run alongside or instead of Epitalon rather than as a separate idea. Course pattern: roughly 10 days on, then off, once or twice a year. To know whether it did anything, sleep is the honest readout — track time to fall asleep and night wakings rather than looking for a blood marker. Run it as an experiment you measure, not a protocol you trust.
How Pinealon works — what 3 residues can and cannot do
Pinealon is Glu-Asp-Arg — a tripeptide, molecular weight 418.4 g/mol, isoelectric point 4.18, net charge about -1.1 at blood pH. Those four numbers are computed from the sequence, not quoted from a vendor.
Glu-Asp-Arg. Three residues, and the sharpest published binding claim in the family — together with an objection that follows from the group's own data and appears nowhere.
The claim. The dedicated EDR review proposes two binding sequences, d(CCTGCC)2 and d(CCAGC)2, and reports finding sites for them in the promoter regions of PPARA, PPARG, SOD2, GPX1 and TPH1 — three possible sites in the PPARA promoter and five for PPARG. These are five- and six-base motifs, which is a real improvement on the four-base sites claimed elsewhere in this class: a six-base site occurs about once every 46 = 4,096 base pairs, so roughly 750,000 times in the human genome rather than twelve million. Better. Still not selective in any sense a molecular biologist would accept, and still a docking prediction rather than a measured binding event.
Now the objection, which comes from Khavinson's own laboratory. The systematic dipeptide-DNA screen from the same group examined which residues appear in the peptides that bind DNA selectively, and recorded this: “although some peptides listed in the table contain positively charged Lys+, none of them include Arg+ in their sequence.” Pinealon leads with arginine. The one systematic, unbiased screen this literature has produced selected against the residue this compound is built around. That does not refute the EDR modeling — a tripeptide is not a dipeptide and the screen did not test EDR — but it is a direct tension between two papers by the same authors, and no page anywhere has noticed it.
Charge, and what it costs. Arginine's guanidinium is positive, the two acidic residues are negative, and the molecule nets out around −1 at blood pH — still repelled by a polyanionic backbone, but less so than a doubly acidic peptide. Arginine is also the residue most associated with genuine DNA-backbone contact in real proteins, which is presumably why it is there. Both things are true at once: the residue makes chemical sense and the group's own screen did not pick it.
Glu-Asp-Arg. Listed in verify_sequences.NEEDS_CITATION — this repo has flagged the sequence as unconfirmed against a primary chemical source rather than assuming it.
What the primary literature on Pinealon actually says
EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease
Khavinson V, Linkova N, Kozhevnikova E, Trofimova S · Molecules 2021;26(1):159 · PMID 33396470
The dedicated EDR review. It names the targets: MAPK/ERK signaling, caspase-3 and p53, the antioxidant enzymes SOD2 and GPX1, PPARA and PPARG, serotonin synthesis and calmodulin. In hypoxia-sensitive rats, EDR raised brain SOD2 and GPx1 activity to the level of hypoxia-resistant animals; it reduced caspase-3 expression and improved Morris-maze learning. Molecular modeling proposes two binding sites, d(CCTGCC)2 and d(CCAGC)2, in the promoters of PPARA, PPARG, SOD2, GPX1 and TPH1.
Peptide Regulation of Gene Expression: A Systematic Review
Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR · Molecules 2021;26(22):7053 · PMID 34834147
Places EDR in the wider class and repeats the nuclear-penetration claim for peptides of two to seven residues.
Systematic search for structural motifs of peptide binding to double-stranded DNA
Kolchina N, Khavinson V, Linkova N, Yakimov A, Baitin D, Afanasyeva A, Petukhov M · Nucleic Acids Research 2019;47(20):10553–10563 · PMID 31598715
The calibration again: computed binding sites are predictions. This is the paper that quantifies how rarely a short peptide binds dsDNA at all.
What is not here. Nothing is indexed under the trade name Pinealon. The EDR record is cell and animal work plus one review. Searched through Europe PMC, PubMed and Google Scholar on 2 September 2026. Naming the gap is more useful than filling it with a paragraph of hedging.
Why the Pinealon evidence is weak — and what it still showed
Almost every human result in this class comes from one school — Vladimir Khavinson's institute in St Petersburg and the groups around it. That means single-center data, collected by the people who developed the compound, rarely blinded, never pre-registered, and reported across enough endpoints that something was always going to move. Read anything below against that.
Specific to Pinealon. The most honest sentence about this compound was written by the people who sell the idea. In their own review, the peptide is 'assumed to enter cells and bind to histone proteins and/or ribonucleic acids.' Assumed. The binding sites are from molecular modeling, not from a chromatin immunoprecipitation or a measured dissociation constant. The animal work is real and the endpoints are real; the step from 'improves maze learning in hypoxia-sensitive rats' to a human cognitive claim is not evidence, it is a hope with a citation attached.
What the data does support, and it is more than most of this catalog. The EDR review reports a genuine, quantified animal result: SOD2 and GPx1 activity in the brain tissue of hypoxia-resistant rats was twice that of hypoxia-sensitive animals, and administering EDR to the sensitive animals raised their brain SOD2 and GPx1 activity to the resistant level. It also reports that EDR reduced caspase-3 expression in brain and improved learning indices in the Morris maze in young and old animals, and prevented caspase-3 activation in neurons of old rats under acute hypoxic hypoxia.
That is a coherent chain — an antioxidant-enzyme effect, an anti-apoptotic effect, and a behavioral readout — in a defined stress model. It is rodent work, it is from the originating group, and the behavioral endpoint is the kind most vulnerable to unblinded scoring. But it is a real experiment with a real control comparison, which is more than can be said for most trade names on these pages.
The specific epistemic position: the best animal mechanism data in the family, a plausible molecular target list, an internal contradiction with the group's own docking screen, and no human trial under this trade name at all.
What is actually measured, and what is not. Measured, in rats: brain SOD2 and GPx1 activity restored from hypoxia-sensitive to hypoxia-resistant levels, a 2-fold difference; reduced caspase-3 expression; improved Morris-maze learning. Modeled, not measured: the d(CCTGCC) and d(CCAGC) binding sites, with 3 predicted sites in the PPARA promoter and 5 for PPARG. Not measured at all: nose-to-brain transfer, plasma half-life, clearance, and any human endpoint.
Not proven is not the same as disproven. Everything above says the evidence is weak. None of it says the compound does nothing. There is no adequately powered trial that ran and came back null, because outside Russia there is essentially no trial at all — this class is unfunded, not failed. A reader who leaves thinking “disproven” has learned something false, and so has one who leaves thinking “proven”.
Pinealon pharmacokinetics — how much of it actually gets in
What degrades it. Two peptide bonds, no protecting groups, an exposed N-terminal glutamate. Serum and tissue aminopeptidases act on exactly this substrate. The quick facts above list “~2-4 hrs”, which is far longer than the rest of the class and is the one half-life figure on these pages worth flagging as doubtful: it has no traceable human study behind it, and there is no structural feature of a bare tripeptide that would produce an hours-scale plasma residence. Treat it as a vendor number.
The transporter route, and why nasal matters here. PEPT1 on the small-intestinal brush border covers “basically all di- and tripeptides”, so Glu-Asp-Arg is inside the substrate range. But Pinealon is sold injectable and nasal rather than oral, and for a compound whose claimed targets are brain antioxidant genes that is the more interesting route: intranasal delivery is the standard way to argue for central access without solving the blood-brain barrier. No study has measured nose-to-brain transfer for this peptide, so the argument is structural rather than demonstrated.
Bound it honestly. An injection is 100% bioavailable by definition and bypasses gut wall and hepatic first-pass entirely. Anything swallowed has to survive gastric acid, pancreatic proteases, the brush-border peptidase layer and the enterocyte cytosol; anything given nasally has to cross respiratory epithelium and then reach brain tissue in quantity. Neither fraction has been measured for Glu-Asp-Arg. The rodent work reporting brain enzyme changes is the only evidence that anything reaches the target, and it is an effect measurement, not an exposure measurement.
The ratio the catalog itself implies. Across this class, the oral products carry a median of roughly 29x more material per day than the injectable ones. Nobody arrived at that by measuring absorption — no oral bioavailability figure has been published for any compound in this family — but the gap is the vendors' own implicit answer to the question: swallowing it is assumed to deliver a small fraction of what an injection delivers, and an injection is fully bioavailable by definition. Treat that as a bound on the plausible exposure, not as a measurement, because a measurement is exactly what is missing.
What would have to be true for Pinealon to work
What would have to be true. Glu-Asp-Arg would have to reach brain tissue in quantity — by nasal transfer or by crossing the blood-brain barrier, neither measured; enter neurons and their nuclei; bind the proposed CCTGCC or CCAGC sites preferentially over the several hundred thousand copies elsewhere in the genome; and raise SOD2 and GPX1 transcription enough to change oxidative-damage chemistry in a human. The rodent work is consistent with the last step. Nothing addresses the first.
The oxidative-stress claim is the testable one, because it names enzymes with measurable downstream products.
- Prediction 1 — MoCA. should move in someone with a measurable deficit, not in someone without one, over a course. A cognitive claim needs a cognitive instrument. A validated screen is free and repeatable; a subjective report is neither.
- Prediction 2 — F2-Isoprostane / Creatinine (Urine). should fall if the SOD2/GPX1 antioxidant claim operates in humans, within a course. This is the direct human readout of the oxidative-stress mechanism the review names, and it is orderable.
- Prediction 3 — hs-CRP (High-Sensitivity C-Reactive Protein). should fall or not move — a rise argues against the mechanism, within a course. Cheap, and it catches the case where something in the vial is provoking rather than damping an immune response.
Run these before and after, not after alone. A single post-course number tells you what your body is doing, not what Pinealon did to it — and that difference is the entire point of testing.
Pinealon versus the alternatives
Pinealon versus Cerluten. Cerluten is the CNS peptide complex; Pinealon is a defined tripeptide sold for overlapping cognitive and neuroprotective goals. One has a sequence, a mass and a purity number but no clinical record under its own name; the other has neither a structure nor a clinical record, and its class was independently graded low to very low certainty. On verifiability Pinealon wins clearly. On evidence neither wins, and pretending otherwise is what the rest of this market does.
And against the credible alternative. For cognitive decline the interventions with human outcome data are blood-pressure control, hearing correction, exercise and sleep — unglamorous, free or cheap, and supported by trials nobody in this industry funded. If you are choosing on evidence, they win outright. The only defensible reason to be on this page is that you have already done them.
What you are actually buying when you buy Pinealon
Defined molecule, verifiable to the milligram. Mass spectrometry confirms the mass; HPLC quantifies purity. Ask for both.
What a certificate cannot verify is the name. This repo lists Pinealon's sequence as needing a primary citation: EDR is thoroughly documented in the peer-reviewed literature as a peptide, with its own dedicated review, but the mapping from the trade name Pinealon to Glu-Asp-Arg is not established by any indexed clinical paper. Treat a vendor's sequence claim as unverified until a mass spectrum backs it — the expected mass is the check, and it is one a buyer can actually make.
Expect/mol. This repo lists the sequence as needing a primary citation, so treat any vendor's sequence claim as unverified until a mass spectrum backs it.
Where to get Pinealon
Pinealon is sold in 2 forms. They are not interchangeable — the dose and the route differ, so pick the one this page describes unless you know why you want another.
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Pinealon
Graded by what exists behind each claim.
Human clinical evidence
- The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
📊 Correlative data
- Used for cognitive goals, often alongside Cerluten or Cortagen. Reported experience is subtle and slow, which is what a gene-expression mechanism would predict — but is also indistinguishable from nothing happening.
- Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.
🧪 Theoretical / extrapolated
- Glu-Asp-Arg — a synthetic tripeptide targeting neurons. Khavinson's group reports it protects neurons against hypoxic and oxidative stress in cell models.
- The shared claim across the Khavinson series: peptides this short are proposed to enter the cell nucleus and bind promoter regions of DNA, shifting tissue-specific gene expression.
- Being a defined tripeptide rather than an extract is the point of this one — you know exactly what is in the vial, which is not true of Cerluten. Same hypothesis, verifiable identity.
What that tier rests on here. The tier above is carried by rodent brain work — antioxidant enzyme activity, caspase-3, maze learning — and by molecular modeling. No human trial is indexed under this trade name.
What community dosing logs are worth → · How to read the Soviet clinical series → · The Khavinson series, in full →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
Cell, rodent, human — and where it stops
Glu-Asp-Arg is the one sequence in this catalog with a basic residue in the middle of the argument. Three residues, 418.4 g/mol, computed net charge about −1.1 at blood pH — the arginine offsets one of the two carboxylates. It is still an anion, but it is the least anionic tripeptide here, and arginine's guanidinium group is exactly the chemistry proteins use to grip the phosphate backbone of DNA. That is the strongest version of the sequence-to-mechanism case anywhere in this class.
In silico and in cells. Kolchina 2019, in Nucleic Acids Research, searched systematically for structural motifs by which short peptides could bind double-stranded DNA — the paper that gives the class its only peer-reviewed structural footing outside its own journals. Khavinson 2021 proposes a gene-expression mechanism for EDR in the pathogenesis of Alzheimer's disease. Linkova 2011 reports peptide-driven differentiation of pineal immune cells.
In animals. Khavinson 2021 is the substantive one: tripeptides of this family in a mouse model of Alzheimer's disease, published in an open-access journal with a neuroprotection endpoint. Kozina 2008 tested short peptides for antihypoxic activity, which is the origin of the hypoxia-tolerance claims that follow this product around.
Where it stops, and it stops abruptly. No human trial of Pinealon exists in any indexed journal. There is no measured brain concentration, no cerebrospinal fluid sample, no pharmacokinetic curve in any species. The transport step is docking Khavinson 2022, not flux. Everything about the human claim is inference from mouse behavior and computed binding energies.
What nobody has tested yet
The measurement that would decide it costs one mouse study. Cortexin's own literature shows how: label the compound, dose an animal, and report brain concentration as a fraction of blood. That has been done once in this whole class, for a different product. Doing it for a defined tripeptide would be easier, not harder, because there is one molecule to label rather than a mixture.
An arginine-free control. If the guanidinium group is doing the DNA binding, then Glu-Asp-Ala should be inactive in the same assay and Glu-Asp-Lys should be partly active. Both are trivial to synthesize and neither appears in the published record. A structure-activity series is the ordinary way a field proves a sequence matters; this field has never run one.
Extrapolation, labeled as such. If EDR is hydrolyzed in serum within minutes, as the chemistry says a tripeptide should be, then whatever reaches the brain is arginine, glutamate and aspartate — three amino acids with their own well-described central effects, arginine being a nitric oxide precursor. A cognitive effect produced that way would be real and would have nothing to do with sequence. Nobody has run the free-amino-acid control arm that separates the two.
Sources read for this page
- Khavinson V, Linkova N, Kozhevnikova E, Trofimova S. EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease. Molecules 2021;26(1):159 · PMID 33396470
- Khavinson V. Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Pharmaceuticals (Basel) 2021 · PMID 34071923
- Kozina LS. Investigation of antihypoxic properties of short peptides. Advances in Gerontology 2008 [Russian] · PMID 18546825
- Kolchina N, Khavinson V, Linkova N, Yakimov A, Baitin D, Afanasyeva A, Petukhov M. Systematic search for structural motifs of peptide binding to double-stranded DNA. Nucleic Acids Research 2019;47(20):10553–10563 · PMID 31598715
- Linkova NS. Peptidegic stimulation of differentiation of pineal immune cells. Bulletin of Experimental Biology and Medicine 2011 · PMID 22803057
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
Pinealon — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Pinealon — safety specifics for this compound
Specific to Pinealon: the nasal route is the part that deserves attention rather than the molecule. Intranasal administration of a reconstituted peptide bypasses the sterility assumptions injection users make automatically, and repeated nasal dosing has its own local irritation profile that nothing in this literature has examined. The mechanistic claim — raising antioxidant enzyme activity in brain tissue — also has no described ceiling, and no study has looked at what sustained SOD2 or GPX1 elevation does over months in an animal that is not under hypoxic stress. The quantified animal result cuts both ways for safety: brain SOD2 and GPx1 activity roughly doubled in hypoxia- resistant rats, which is a real antioxidant effect and therefore a real biological one. Anything with an effect that size in nervous tissue has a dose above which it is no longer helpful, and that dose has been established in 0 studies of any species. Intranasal delivery compounds it — a reconstituted peptide sprayed into the nose has neither the sterility discipline of an injection nor a published local-irritation profile.
Pinealon — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Pinealon moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- How the forms differ in dose
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Pinealon in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Pinealon
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Pinealon — frequently asked questions
What is the amino acid sequence of Pinealon?
Pinealon is Glu-Asp-Arg — 3 residues, 418.4 g/mol, isoelectric point 4.18. Those figures are computed from the sequence rather than quoted.
Can a peptide that short really bind DNA?
Not the way a transcription factor does. A zinc finger needs about 30 residues to read three base pairs. When Khavinson's group docked all 400 dipeptides against DNA, the vast majority could not bind double-stranded DNA at all. The claim is a computational prediction supported by gene-expression readouts in cells, not a measured binding event.
Is there a human trial of Pinealon?
Nothing is indexed under the trade name Pinealon. The EDR record is cell and animal work plus one review.
What should I measure if I run Pinealon?
Before and after, not after alone. The falsifiability section on this page names the specific markers, the direction each should move and the timescale — and says what a null result would rule out.
References & further reading
- Khavinson V, Linkova N, Kozhevnikova E, Trofimova S — EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease · Molecules 2021;26(1):159 · PMID 33396470
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR — Peptide Regulation of Gene Expression: A Systematic Review · Molecules 2021;26(22):7053 · PMID 34834147
- Kolchina N, Khavinson V, Linkova N, Yakimov A, Baitin D, Afanasyeva A, Petukhov M — Systematic search for structural motifs of peptide binding to double-stranded DNA · Nucleic Acids Research 2019;47(20):10553–10563 · PMID 31598715
Pinealon inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Pinealon is used for
Pinealon appears under 2 goals in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Pinealon is the rhythm arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.